Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
相关临床试验
74
43 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
2010
进行中（未招募）
42
56.8%
Approved For Marketing
1
1.4%
已完成
24
32.4%
Enrolling By Invitation
1
1.4%
招募中
6
8.1%
